Get the Stockscreener App
1.85
13.08%
-0.29
Pasithea Therapeutics Corp stock is traded at $1.85, with a volume of 309.59K.
It is down -13.08% in the last 24 hours and down -37.79% over the past month.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia.
See More
Previous Close:
$2.14
Open:
$2.12
24h Volume:
309.59K
Relative Volume:
0.31
Market Cap:
$2.71M
Revenue:
-
Net Income/Loss:
$-16.28M
P/E Ratio:
-0.133
EPS:
-13.91
Net Cash Flow:
$-13.75M
1W Performance:
-16.96%
1M Performance:
-37.79%
6M Performance:
-60.84%
1Y Performance:
-69.15%
1-Day Range:
$1.83
$2.12
1-Week Range:
$1.83
$3.85
52-Week Range:
$1.83
$9.25
Pasithea Therapeutics Corp Stock (KTTA) Company Profile
Name
Pasithea Therapeutics Corp
Sector
Industry
Phone
(818) 422-6172
Address
2110 NARCISSUS CT, VENICE
Compare KTTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KTTA
Pasithea Therapeutics Corp
|
1.87 | 2.71M | 0 | -16.28M | -13.75M | -13.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.49 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.15 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.40 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.24 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.86 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Pasithea Therapeutics Corp Stock (KTTA) Latest News
Big Mid-Week Move From This Small Biotech - The Globe and Mail
KTTA stock touches 52-week low at $2.19 amid market challenges - MSN
Pasithea Therapeutics Corp (KTTA) Stock: Navigating Drops and Gains - The InvestChronicle
Understanding KTTA’s financial ratios: A beginner’s guide - US Post News
Pasithea (KTTA) Stock Spikes On Its Latest Clinical Trial Milestone - Stocks Telegraph
Pasithea Therapeutics Shares Rise After Positive Safety Review for Cancer Treatment - MarketWatch
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - Marketscreener.com
Top Premarket Gainers -February 05, 2025 at 07:47 am EST - Marketscreener.com
Pasithea announces Safety Review Committee recommendation - TipRanks
Pasithea's PAS-004 advances in cancer trial with no toxicities - Investing.com
Pasithea's PAS-004 advances in cancer trial with no toxicities By Investing.com - Investing.com UK
Pasithea Therapeutics Announces Positive Safety Review - GlobeNewswire
Clinical Trial Breakthrough: Cancer Drug Shows Unprecedented Safety Profile in Phase 1 - StockTitan
Pasithea Therapeutics Corp. (NASDAQ:KTTA) Short Interest Up 37.2% in December - Defense World
Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4 - GlobeNewswire
Pasithea Therapeutics Corp. Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4 - Marketscreener.com
KTTA stock touches 52-week low at $2.33 amid market challenges - Investing.com Australia
KTTA stock touches 52-week low at $2.33 amid market challenges By Investing.com - Investing.com South Africa
Pasithea Therapeutics Expands Phase 1 Cancer Trial to Europe, Advances PAS-004 Testing - StockTitan
Analyzing Galecto (NASDAQ:GLTO) and Pasithea Therapeutics (NASDAQ:KTTA) - Defense World
Analyzing Pasithea Therapeutics (NASDAQ:KTTA) and MusclePharm (OTCMKTS:MSLP) - Defense World
KTTA stock touches 52-week low at $2.72 amid market challenges - Investing.com Nigeria
KTTA stock touches 52-week low at $2.72 amid market challenges By Investing.com - Investing.com South Africa
KTTA stock touches 52-week low at $2.87 amid market challenges - Investing.com Nigeria
Pasithea Therapeutics Announces Positive Safety Review Committee Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - Marketscreener.com
Pasithea's PAS-004 Drug Shows Strong Safety Profile in Phase 1 Trial, Zero Toxicity Issues | KTTA Stock News - StockTitan
Pasithea Therapeutics (NASDAQ:KTTA) Shares Up 2.4% – Still a Buy? - Defense World
KTTA stock touches 52-week low at $3.19 amid market challenges By Investing.com - Investing.com South Africa
KTTA stock touches 52-week low at $3.19 amid market challenges - Investing.com UK
ARMISTICE CAPITAL, LLC Acquires New Stake in Pasithea Therapeuti - GuruFocus.com
KTTA stock touches 52-week low at $3.4 amid market challenges - Investing.com Australia
Interview with the CEO: Pasithea Therapeutics Corp. (NASDAQ:KTTA) - The Wall Street Transcript
KTTA stock touches 52-week low at $3.6 amid market challenges - Investing.com Australia
KTTA stock touches 52-week low at $3.6 amid market challenges By Investing.com - Investing.com South Africa
pasithea therapeutics corp Earnings dates - RTTNews
(KTTA) Investment Analysis - Stock Traders Daily
Allogene Therapeutics (ALLO) Stock Drops Over 5% Amid Market Act - GuruFocus.com
Was there any good news for Pasithea Therapeutics Corp (KTTA) stock in the last session? - US Post News
Allogene Therapeutics (ALLO) Stock Jumps by 5.15% - GuruFocus.com
Market cap of Pasithea Therapeutics Corp [KTTA] reaches 6.08M – now what? - The DBT News
PAS-004 Has Tolerable Safety Profile and Preliminary Efficacy in MAPK-Driven Solid Tumors - OncLive
Pasithea Therapeutics Corp. (NASDAQ:KTTA) Stock Gains After Private Placement - DRP Journal
Pasithea Therapeutics drops 19% on $5M private placement - MSN
Pasithea Therapeutics Corp Stock (KTTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):